Brokerages Expect Trillium Therapeutics Inc (TRIL) Will Announce Earnings of -$0.67 Per Share

Share on StockTwits

Equities analysts expect Trillium Therapeutics Inc (NASDAQ:TRIL) (TSE:TR) to report ($0.67) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Trillium Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.55) and the lowest estimate coming in at ($0.78). Trillium Therapeutics posted earnings per share of ($0.84) during the same quarter last year, which would indicate a positive year-over-year growth rate of 20.2%. The business is expected to announce its next earnings results on Friday, November 9th.

According to Zacks, analysts expect that Trillium Therapeutics will report full year earnings of ($2.49) per share for the current fiscal year, with EPS estimates ranging from ($2.60) to ($2.34). For the next financial year, analysts forecast that the business will post earnings of ($2.20) per share, with EPS estimates ranging from ($2.53) to ($1.79). Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that cover Trillium Therapeutics.

Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) last posted its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.05).

Several analysts have recently commented on TRIL shares. Zacks Investment Research cut Trillium Therapeutics from a “buy” rating to a “hold” rating and set a $7.00 price target for the company. in a report on Thursday, June 28th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Trillium Therapeutics in a research note on Monday, August 13th.

Trillium Therapeutics stock traded down $0.01 during mid-day trading on Tuesday, reaching $3.71. 40,931 shares of the company were exchanged, compared to its average volume of 188,441. Trillium Therapeutics has a twelve month low of $3.60 and a twelve month high of $13.30.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Platinum Investment Management Ltd. acquired a new stake in shares of Trillium Therapeutics during the first quarter worth approximately $1,255,000. Baker BROS. Advisors LP increased its position in Trillium Therapeutics by 25.0% during the 2nd quarter. Baker BROS. Advisors LP now owns 511,763 shares of the biotechnology company’s stock valued at $3,071,000 after purchasing an additional 102,440 shares during the period. Renaissance Technologies LLC increased its position in Trillium Therapeutics by 245.3% during the 2nd quarter. Renaissance Technologies LLC now owns 144,000 shares of the biotechnology company’s stock valued at $864,000 after purchasing an additional 102,300 shares during the period. Stanley Laman Group Ltd. increased its position in Trillium Therapeutics by 26.7% during the 2nd quarter. Stanley Laman Group Ltd. now owns 137,091 shares of the biotechnology company’s stock valued at $823,000 after purchasing an additional 28,907 shares during the period. Finally, Wealth Alliance Advisory Group LLC purchased a new position in Trillium Therapeutics during the 3rd quarter valued at $126,000. 48.62% of the stock is currently owned by institutional investors and hedge funds.

Trillium Therapeutics Company Profile

Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies, and solid tumors and mycosis fungoides.

Read More: Asset Allocation and Your Retirement

Get a free copy of the Zacks research report on Trillium Therapeutics (TRIL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

NXP Semiconductors NV  Stake Boosted by Royal London Asset Management Ltd.
NXP Semiconductors NV Stake Boosted by Royal London Asset Management Ltd.
Keybank National Association OH Has $52.53 Million Holdings in Roper Technologies Inc
Keybank National Association OH Has $52.53 Million Holdings in Roper Technologies Inc
Keybank National Association OH Sells 74,390 Shares of iShares MBS ETF
Keybank National Association OH Sells 74,390 Shares of iShares MBS ETF
iShares MSCI Emerging Markets ETF  Holdings Cut by Keybank National Association OH
iShares MSCI Emerging Markets ETF Holdings Cut by Keybank National Association OH
National Asset Management Inc. Raises Stake in CME Group Inc
National Asset Management Inc. Raises Stake in CME Group Inc
Micron Technology, Inc.  Shares Sold by National Asset Management Inc.
Micron Technology, Inc. Shares Sold by National Asset Management Inc.


© 2006-2018 Ticker Report